<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PHYSOSTIGMINE SALICYLATE</span><br/>(fi-zoe-stig'meen)<br/><span class="topboxtradename">Antilirium<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">cholinergic (parasympathomimetic)</span>; <span class="classification">cholinesterase inhibitor</span><br/><b>Prototype: </b>Neostigmine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Reversible anticholinesterase and tertiary amine. Chief effect is increasing concentration of acetylcholine at cholinergic
         transmission sites which prolongs and exaggerates its action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Similar to neostigmine in actions and adverse effects, but produces greater secretion of glands, constriction of pupils, and
         effect on BP and less action on skeletal muscle. Also has direct blocking action on autonomic ganglia. Parenteral physostigmine
         can produce transient decrease in manic symptoms as well as precipitate mental depression.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To reverse CNS and cardiac effects of tricyclic antidepressant overdose, to reverse CNS toxic effects of atropine, scopolamine,
         and similar anticholinergic drugs, and to antagonize CNS depressant effects of diazepam. <b>Orphan Drug:</b> For hereditary ataxias.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Asthma; diabetes mellitus; gangrene, cardiovascular disease; mechanical obstruction of intestinal or urogenital tract; any
         vagotonic state; secondary glaucoma; inflammatory disease of iris or ciliary body; concomitant use with choline esters (e.g.,
         methacholine, bethanechol) or depolarizing neuromuscular blocking agents (e.g., decamethonium, succinylcholine). Safety during
         pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Epilepsy; Parkinsonism; bradycardia; hyperthyroidism; peptic ulcer; hypotension.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Reversal of Anticholinergic Effects</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> 0.53 mg (IV not faster than 1 mg/min), repeat as needed<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.010.03 mg/kg, may repeat q1520 min (max: total dose of 2 mg)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular/</span><span class="adminroutetype">Intravenous</span><br/><ul>
<li>Give undiluted.</li>
<li>Use only clear, colorless solutions. Red-tinted solution indicates oxidation, and such solutions should be discarded.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li> 					Note: Verify correct rate of IV injection for infants or children with physician. 				</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a slow rate, no more than 1 mg/min. Rapid administration and overdosage can cause a cholinergic crisis.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Sweating,</span> <span class="speceff-life">cholinergic crisis (acute toxicity)</span>, hyperactivity, respiratory distress, convulsions. <span class="typehead">CNS:</span> Restlessness, hallucinations, twitching, tremors, <span class="speceff-common">sweating,</span> weakness, ataxia, convulsions, <span class="speceff-life">collapse</span>. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, epigastric pain, diarrhea, salivation.</span> <span class="typehead">Urogenital:</span> Involuntary urination or defecation. <span class="typehead">Special Senses:</span> Miosis, <span class="speceff-common">lacrimation,</span> rhinorrhea. <span class="typehead">Respiratory:</span> Dyspnea, bronchospasm, <span class="speceff-life">respiratory paralysis, pulmonary edema</span>. <span class="typehead">Cardiovascular:</span> Irregular pulse, palpitation, bradycardia, rise in BP. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Antagonizes effects of <b>echothiophate,</b> <b>isoflurophate.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from mucous membranes, muscle, subcutaneous tissue; 1012% absorbed from GI tract. <span class="typehead">Onset:</span> 38 min IM/IV. <span class="typehead">Duration:</span> 0.55 h IM/IV. <span class="typehead">Distribution:</span> Crosses blood-brain barrier. <span class="typehead">Metabolism:</span> Metabolized in plasma by cholinesterase. <span class="typehead">Elimination:</span> Excretion not fully understood; small amounts excreted in urine. <span class="typehead">Half-Life:</span> 1540 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs and state of consciousness closely in patients receiving drug for atropine poisoning. Since physostigmine
            is usually rapidly eliminated, patient can lapse into delirium and coma within 1 to 2 h; repeat doses may be required.
         </li>
<li>Monitor closely for adverse effects related to CNS and for signs of sensitivity to physostigmine. Have atropine sulfate readily
            available for clinical emergency.
         </li>
<li>Discontinue parenteral or oral drug if following symptoms arise: Excessive salivation, emesis, frequent urination, or diarrhea.</li>
<li>Eliminate excessive sweating or nausea with dose reduction.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>